威高血液淨化透露，計劃在港上市後的適當時間進行A股的發行及上市，並已就A股發行提交上市前輔導的備案，有關申請已於2020年12月獲中國證監會山東監管局受理，目前尚未確定擬發售的A股的規模及範圍。Veigor's blood purification submits a listing application to the Stock Exchange with the joint sponsors Citi, Huatai International and Huaxing Capital. Earlier, external news said that Weigao's blood purification target raised about $500 million.
The company mainly provides comprehensive blood purification products, including dialyzer, dialysis machine, blood line and other hemodialysis products, peritoneal dialysis products such as peritoneal dialysis. Currently, there are 219 self-developed hemodialysis products. According to market research institutes, the company's dialyzer sales market share in 2021 was 32.4% and blood pipeline sales market share of 32.6%, ranked first in the Mainland market.
According to the preliminary prospectus, the revenue from continuing operations of Weigao blood purification last year amounted to RMB 2,947 billion (the same below), up 14.9% YoY while profit for the year decreased 12.6% YoY to $269 million.
Veigao blood purification revealed that it plans to issue and list A shares at an appropriate time after listing in Hong Kong. The application has been accepted by the China Securities Commission Shandong Regulatory Authority in December 2020 and has not yet determined the size and scope of the A-shares to be offered.